Skip to main content
. Author manuscript; available in PMC: 2022 Jan 17.
Published in final edited form as: Leukemia. 2021 Jul 17;35(10):2854–2861. doi: 10.1038/s41375-021-01342-x

Figure 2: AE score by treatment group, across all assessments/cycles, the first 6 cycles of treatment, and after 6 cycles of treatment.

Figure 2:

Box-and-whisker plots show the distribution of AE scores for patients treated with bendamustine plus rituximab (BR) or ibrutinib regimens (IBR). Across all cycles and in the first 6 cycles of treatment, 176 patients in the BR group had AE scores and 361 patients in the IBR group had AE scores. Among those who completed 6 cycles of therapy, after 6 cycles 117 patients in the BR group had AE scores and 325 patients in the IBR group had AE scores. AE scores for six outliers are not shown in the plots (AE score of 59 with BR across all cycles and during the first 6 cycles of treatment, AE score of 34 with IBR during the first 6 cycles of treatment, AE score of 33 with BR across all cycles and during the first 6 cycles of treatment, and AE score of 29.3 with BR during the first 6 cycles of treatment) to better visualize the AE score distributions.